Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11491238 Exon skipping oligomer conjugates for muscular dystrophy

Patent 11491238 was granted and assigned to Sarepta Therapeutics on November, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Sarepta Therapeutics

Current Assignee

Sarepta Therapeutics

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

114912380

Patent Inventor Names

Richard K. Bestwick0

Frederick Joseph Schnell0

Date of Patent

November 8, 2022

Patent Application Number

169382740

Date Filed

July 24, 2020

Patent Citations

‌

US Patent 10765760 Exon skipping oligomer conjugates for muscular dystrophy

‌

US Patent 10337003 Compositions for treating muscular dystrophy

‌

US Patent 10758629 Exon skipping oligomer conjugates for muscular dystrophy

‌

US Patent 11000600 Exon skipping oligomer conjugates for muscular dystrophy

Patent Primary Examiner

‌

Kimberly Chong

Antisense oligomers complementary to a selected target site in the human dystrophin gene to induce exon 52 skipping are described.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11491238 Exon skipping oligomer conjugates for muscular dystrophy

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API